This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers
by Zacks Equity Research
Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers
Bet on These 5 GARP Stocks Based on Low PEG Ratio
by Zacks Equity Research
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Company News For Nov 10, 2017
by Zacks Equity Research
Companies in the News are: ROKU,M,SEDG,PRGO
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.
4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
by Zacks Equity Research
The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
by Zacks Equity Research
Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
Company News For August 11, 2017
by Zacks Equity Research
Companies in the new are: PRGO,KSS,EAT,LYV
Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
by Arpita Dutt
This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Perrigo Company Gets FDA Approval for Generic Topical Gel
by Zacks Equity Research
Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.
Why Is Perrigo (PRGO) Up 5% Since the Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for June 01, 2017
by Zacks Equity Research
Companies in the News are: KORS,ADI,PRGO,JILL
Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact
by Zacks Equity Research
Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
Generic Drugmakers Tumble as Perrigo Discloses DoJ Search
by Arpita Dutt
With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.
Perrigo Launches First to Market OTC Equivalent of Rogaine
by Zacks Equity Research
Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).
Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View
by Zacks Equity Research
The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
by Zacks Equity Research
Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.
Is Perrigo Company (PRGO) a Great Stock for Value Investors?
by Zacks Equity Research
Let's delve into the value metrics of Perrigo Company (PRGO) and determine whether it is a good value investment right now.